IGF-1 LR3 1mg

£34.99

  • ≥99% Purity (HPLC)
  • Batch-tested & CoA available
  • For research use only

IGF-1 LR3 is an 83-amino-acid recombinant growth-factor analogue of human IGF-1, supplied lyophilised for controlled in-vitro studies of growth-factor signalling.

A 13-residue N-terminal extension and an Arg³ substitution minimise IGF-binding-protein interaction, supporting sustained availability in experimental media. Handle gently and do not vortex. For laboratory research only. Not for human use.

FOR LABORATORY RESEARCH USE ONLY

This product is supplied exclusively for scientific laboratory research. It is not intended for human or veterinary use or administration, therapeutic use, diagnostic use or clinical application.

Avanti Peptides does not provide advice regarding human administration, dosage, injection, reconstitution for administration, treatment protocols or therapeutic use.

Regulatory status

This product is sold as a laboratory research material and is not offered or promoted as a medicinal product. No therapeutic or medical claims are made for this product.

SKU: IGF1LR3-1MG Category: Tags: ,

Description

≥99% Purity (HPLC)
Batch-tested & CoA available
Lyophilised — stable at room temp
For research use only

About IGF-1 LR3

IGF-1 LR3 is an 83-amino-acid recombinant analogue of human insulin-like growth factor-1, supplied as a lyophilised research compound. A 13-residue N-terminal extension and an arginine substitution at position 3 sharply reduce binding to IGF-binding proteins, which is why this growth-factor analogue sustains measurable activity in serum-containing culture where native IGF-1 is rapidly sequestered.

Why researchers choose Avanti Peptides IGF-1 LR3: A 9 kDa protein is far more fragile than a short peptide — this material is lyophilised, sealed and released against identity and purity specifications so it arrives intact.

Key features of IGF-1 LR3

  • Recombinant growth-factor analogue (83-amino-acid)
  • Sequence: 83-residue recombinant analogue of human IGF-1 (13-residue N-terminal extension; Arg substitution at position 3) (83 amino acids)
  • Lyophilised solid — stable, easy to store, straightforward to reconstitute
  • Unit size: 1 mg / vial
  • Every batch released only after identity, purity, and appearance QC
  • Certificate of Analysis (CoA) and batch documentation available on request

IGF-1 LR3 technical specifications

Product name IGF-1 LR3
Synonyms Long R3 IGF-1; Long Arg3 IGF-1; LR3-IGF-1
Amino-acid sequence 83-residue recombinant analogue of human IGF-1 (13-residue N-terminal extension; Arg substitution at position 3)
Class Recombinant growth-factor analogue (83-amino-acid)
Molecular formula C₄₀₀H₆₂₅N₁₁₁O₁₁₅S₉
Molecular weight ~9,117.6 g/mol
CAS number 946870-92-4
Purity ≥99% (HPLC)
Physical form Lyophilised powder
Appearance White to off-white solid
Unit size 1 mg / vial
Note Higher molecular weight than standard research peptides — handle gently and avoid vortexing

Reconstituting and storing IGF-1 LR3

  1. Before reconstitution: Store lyophilised vials at 2–8 °C, protected from light and moisture.
  2. Equilibrate: Allow vial and diluent to reach room temperature before opening.
  3. Reconstitute: Add Bacteriostatic Water (10 ml recommended). Swirl gently — do not vortex.
  4. After reconstitution: Store at 2–8 °C. Prepare aliquots to minimise freeze–thaw cycles.
  5. Compatibility: Use only within protocols that comply with your institution’s SOPs and local regulations.

Looking for complementary materials? See Bacteriostatic Water 10ml — recommended diluent, AOD-9604 5mg, Ipamorelin 5mg — GH-axis comparator.

IGF-1 LR3 in research

Researchers use IGF-1 LR3 to probe cell growth and differentiation, protein-synthesis signalling and glucose-metabolism pathways in non-clinical models. Because reduced IGFBP affinity keeps free ligand available for longer, this growth-factor analogue gives more consistent dose-response curves than native IGF-1 in media containing binding proteins. Reconstitute gently and avoid vortexing to limit shear denaturation.

Synthesis and quality assurance

Avanti Peptides manufactures IGF-1 LR3 via controlled, validated solid-phase peptide synthesis (SPPS) to deliver high purity and lot-to-lot consistency. Each batch undergoes identity verification, HPLC purity analysis (≥99%), and appearance inspection before release.

Frequently asked questions about IGF-1 LR3

What is IGF-1 LR3?
IGF-1 LR3 is a 83-amino-acid peptide (sequence: 83-residue recombinant analogue of human IGF-1 (13-residue N-terminal extension; Arg substitution at position 3)). It is used exclusively for in-vitro laboratory research. See the product overview above for full context.
How should I store the peptide?
Store lyophilised vials at 2–8 °C, away from light and moisture. After reconstitution, keep at 2–8 °C and use aliquots to minimise freeze–thaw cycles.
What diluent should I use for reconstitution?
Most laboratories use Bacteriostatic Water (10 ml). Always follow your lab’s standard operating procedures (SOPs) for the specific assay.
Do you provide batch documentation / Certificate of Analysis?
Yes. Batch documentation including test results (CoA) is available on request. If it is not attached to your order confirmation, contact our support team and we will add it immediately.
Is this product intended for human use?
No. This material is strictly for laboratory research only and is not intended for human consumption, clinical application, or veterinary use.

Legal & safety notice

For research use only. Avanti Peptides supplies this material strictly for laboratory research. This product is not a medication, food supplement, or cosmetic and is not intended for human or veterinary use. By purchasing, you confirm that you are a qualified researcher and will handle the material in accordance with your institution’s policies and all applicable laws and regulations.

External resources for researchers